639858-71-2Relevant academic research and scientific papers
Discovery and evaluation of N-cyclopropyl-2,4-difluoro-5-((2-(pyridin-2- ylamino)thiazol-5-ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2
Borzilleri, Robert M.,Bhide, Rajeev S.,Barrish, Joel C.,D'Arienzo, Celia J.,Derbin, George M.,Fargnoli, Joseph,Hunt, John T.,Jeyaseelan Sr., Robert,Kamath, Amrita,Kukral, Daniel W.,Marathe, Punit,Mortillo, Steve,Qian, Ligang,Tokarski, John S.,Wautlet, Barri S.,Zheng, Xiaoping,Lombardo, Louis J.
, p. 3766 - 3769 (2007/10/03)
Substituted 3-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)-amino)benzamides were identified as potent and selective inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2) kinase activity. The enzyme kinetics associated with the VEGFR-2 inhibi
Heterocyclic inhibitors of kinases
-
Page/Page column 14, (2008/06/13)
The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
